u/hassan_chowdhury

Discharge from a specialist service at goal is a normal end point of that pathway. Whether prescribing continues in primary care afterwards is a local decision and is worth asking about at the start rather than at the end.

The shortage list is the legal hinge: the permissions that allow certain compounding to happen at scale are tied to a drug’s shortage status, which ch

Adding one thing — ask for the facility name. Most will give it, and the ones that will not have answered you.

the API source is the question nobody asks and everybody should

Not convinced comparison helps here. The people posting the fastest results are the tail of a distribution, not the middle.

Not convinced — the US threads are a different system entirely and importing their advice here does real harm.

Correction: that threshold is your ICB’s, not a national one. They differ and they change by year.

Disagree that the pace matters as much as you think. Durable is better than fast and nobody posts about durable.

How many weeks between the two scans?

resistance training first, cardio if there is time left

Not convinced. You are comparing a compounded concentration with a branded one and assuming they match.

Stalled for 7 weeks and measured my waist out of stubbornness. It had moved. The scale had not.

the second-level appeal is where things actually turn

identity and quantity are two questions and most documents answer one

Salt form matters for mass: a preparation specified as one salt and dosed as the free base gives you a different amount of peptide for the same number on the label.

That is the catalogue certificate rather than the batch-specific one. Same layout, completely different status.

the shortage list is the whole legal hinge and people skip it

Salt form matters for mass: a preparation specified as one salt and dosed as the free base gives you a different amount of peptide for the same number

Agreed — and the follow-up question is what the beyond-use date is based on.

Correction: that is net peptide content, not purity. Different number, different meaning, and the document says so if you read the row label.

Push back: your plan is an employer plan, which changes both the appeal path and who the regulator is.

prior authorisation criteria change every plan year

Careful — "the metadata looks odd" is a reason to ask a question, not a conclusion. Re-issues are ordinary.

Ask what the stability statement was written against — temperature, light, and whether it was the lyophilised powder or the reconstituted solution. Those are three different claims.